Aeon Biopharma, INC Schedule 13G passive stakes

Stonepine Capital Management, LLC and its affiliates have reported a 9.9% beneficial ownership in AEON Biopharma, Inc. Class A Common Stock.

Alta Partners LLC has reported a 2.1% beneficial ownership stake in AEON Biopharma, Inc., including shares from warrants, as detailed in its latest Schedule 13G amendment.

Alta Partners LLC has disclosed a beneficial ownership of 5.17% of AEON Biopharma, Inc.'s common stock, totaling 586,335 shares.

Jorey Chernett has filed a Schedule 13G, revealing a significant beneficial ownership of 9.98% in AEON Biopharma, Inc., holding 1,128,500 shares of common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, revealing a substantial reduction in its beneficial ownership of AEON Biopharma, Inc.'s Class A Common Stock to 4.11%.

S.H.N. Financial Investments Ltd. has reported a complete divestment of its beneficial ownership in AEON Biopharma, Inc.'s Class A Common Stock, reducing its stake from 5,400,000 shares to 0 shares.

Polar Asset Management Partners Inc. has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in AEON Biopharma Inc.'s Class A Common Stock as of March 31, 2025.

Alta Partners LLC has filed a Schedule 13G, reporting beneficial ownership of 6.23% of AEON Biopharma, Inc.'s common stock, indicating a substantial institutional investment.

Dauntless Investment Group, LLC has disclosed a 9.74% passive ownership stake in AEON Biopharma, Inc., holding 108,224 common shares.

Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, disclosing a 3.81% beneficial ownership stake in AEON Biopharma, Inc. as of December 31, 2024.

Polar Asset Management Partners Inc. has filed an amended Schedule 13G, revealing a 6.9% beneficial ownership stake in AEON Biopharma Inc.'s Class A ordinary shares as of December 31, 2024.

S.H.N. Financial Investments Ltd. has reported a 6.0% beneficial ownership stake in AEON Biopharma, Inc.'s Class A Common Stock, as detailed in a recent Schedule 13G filing.

L1 Capital Global Opportunities Master Fund, Ltd. has disclosed a 9.99% beneficial ownership stake in AEON Biopharma, Inc., comprising Class A Common Stock and warrants.

Several investment entities and Michael Bigger disclosed a significant beneficial ownership in AEON Biopharma, Inc. as of January 6, 2025, but subsequently sold all their holdings.